Page 329«..1020..328329330331..340350..»

Call for expressions of interest: Expert(s) to conduct systematic literature reviews of the evidence on tuberculosis and diabetes – World Health…

Posted: July 27, 2022 at 2:39 am

The World Health Organization (WHO) Global Tuberculosis Programme in collaboration with the Noncommunicable Diseases Department has initiated a process to review the evidence on TB and diabetes and the related interventions to address the joint burden of TB and diabetes.

In 2011, WHO and the International Union against Tuberculosis and Lung Disease published the Collaborative framework for care and control of tuberculosis and diabetes, which contains recommendations on the collaborative management of TB and diabetes. This framework has helped to kick-start collaborative action on TB and diabetes but there are still challenges in implementation and scale-up. WHO will therefore be developing an operational handbook to support countries in the implementation of current WHO recommendations and collaborative activities on TB and diabetes.

To inform the operational handbook, WHO is seeking expressions of interest from academic institutions or other entities with relevant expertise and experience in systematic reviews, synthesis and quality assessment of the available data (following the GRADE framework and in line with Handbook on guideline development, 2nd edition), summarize the results, and write a descriptive report detailing the methods and findings of the reviews. The candidate entity should be able to work independently as well as interact regularly and collaboratively with the WHO Global TB Programme team and NCD Department as well as other technical experts as required. Please review theterms of referencefor details of the work and requirements.

Please submit to the WHO Global TB Programme an expression of interest letter specifying details on the relevant capacity and experience of the candidates in similar type of work on systematic reviews and meta-analyses, together with the resumes of persons to be involved.

Please send your submissions to the WHO Global TB Programme at[emailprotected]and [emailprotected] by close of business on 11thAugust 2022. The expressions of interest received will go through a review process and the selected candidates will be notified on completion of the review process. The selected candidates will be required to develop a proposal for the evidence summary to be conducted along with details of a budget estimate to be submitted to the WHO Global TB Programme.

Read more here:
Call for expressions of interest: Expert(s) to conduct systematic literature reviews of the evidence on tuberculosis and diabetes - World Health...

Posted in Diabetes | Comments Off on Call for expressions of interest: Expert(s) to conduct systematic literature reviews of the evidence on tuberculosis and diabetes – World Health…

Man with diabetes and dementia reported missing from Covina – CBS Los Angeles

Posted: July 27, 2022 at 2:39 am

Police Thursday sought the public's help in locating a 63-year-old man who was last seen in the Covina area.

Antonio Ortega, who authorities say is diabetic, suffers from dementia and is 80% blind, was last seen at 12:40 a.m. Wednesday on the 21000 block of East Covina Boulevard.

Ortega is described as a Latino man who is 5 feet, 6 inches tall, and weighs 200 pounds. He has brown eyes and gray hair. and was last seen wearing a blue shirt, blue shorts and black sandals.

Authorities say Ortega is dependent on medication.

Anyone with information about Ortega or knows of his whereabouts was asked to call the Sheriff's Missing Persons Unit at 323-890-5500. Anonymous tips can be called into Crime Stoppers at 800-222-8477 or submitted online at lacrimestoppers.org.

The CBS LA Staff is a group of experienced journalists who bring you the content on CBSLA.com.

See the original post:
Man with diabetes and dementia reported missing from Covina - CBS Los Angeles

Posted in Diabetes | Comments Off on Man with diabetes and dementia reported missing from Covina – CBS Los Angeles

Blood, sweat, and many miles for cellular therapy – Martha’s Vineyard Times

Posted: July 27, 2022 at 2:38 am

Bob Falkenberg, a 13-year leukemia survivor, is just one example of a transplant recipient that Be the Match (BTM) has been able to treat and save by connecting him with a blood marrow donor. But while Falkenberg is a face of success in matching patients with a donor, the 12,000 patients diagnosed with life-threatening blood cancers or other blood cell diseases each year are not always as easily treated, especially with financial barriers and a disparity in match rates for nonwhite patients.

Just two years after his transplant, and with a push from a 100-mile bike ride challenge from his friend, Falkenberg has been biking to raise money and awareness for the need for transplant donors for the past 11 years. He and his team of nine riders took to the Island July 20 to continue this support for Be the Match, part of their monthlong East Coast ride event, Tour De TC. This annual bike ride raises critical funds for Be the Match, with this years ride aimed at raising enough funds to financially support 25 families in need of treatment.

In his past years of biking for Be tThe Match, Falkenberg has embarked on rides from Boston to Key West, Vancouver to San Francisco, and Vancouver to Florida. His hope is to hit all 50 states with future rides. For the second half of this years July tour, the crew has already gone from Boston to the Cape and Marthas Vineyard, but will continue on via ferry to Rhode Island and Connecticut. From there, the crew will ferry to the east end of Long Island and into New York City to meet people from the transplant center there. Finally, the riders will head to the childrens hospital in Philadelphia.

In past years, the rides have been more family-and-friends-oriented, according to Falkenberg. But this year, he said that the rides have been more open to participation. From this, he added, they have gotten a larger response, and have already raised $100,000 for this year, three times as much as last years raised funds. This is just the start, as he expects they will double all raised funds from this year next year.

Funds raised go toward adding more donors to the Be the Match registry, research to ease the safety of transplant procedures, as well as financial assistance for families and patients in need of transplants and in post-transplant recovery. For adding donors, there is a cost to do the human leukocyte antigen (HLA) tests in order to add donors to the registry, and match them to patients. Funds for researching the transplant procedures include identifying and preventing issues that can impact chance of survival, which has increased from 30 percent to closer to 50 percent in the past 13 years, according to Falkenberg. For many people, the journey of treatment and recovery can even be such a financial toll it can prevent patients from moving forward with potentially lifesaving procedures if careers are put on hold, decreasing household income, says BTM in an information sheet.

Leukemia is the No. 1 childhood cancer, so a lot of this is for kids. When the parents travel, they have to stay there for a long time sometimes, Falkenberg says, which takes time away from work and puts financial strain on family support. There are financial grants through BTM that increase this family and patient support while covering costs that insurance will not.

Money is not the only thing that decreases the success of patient survival, as there has grown to be a disparity in the diversity of donors. According to BTM, out of almost 300,000 potential U.S. donors added to the registry last year, only 31 percent were ethnically diverse. Falkenberg commented on this issue, saying, Theres about 20 million people on the registry, but if youre Black, you only have about a 29 percent chance right now of finding a single donor on the registry, because there just arent enough Black donors, and its tied to your DNA and ethnicity. Falkenberg also said that there is a similar struggle for Asian or Pacific Islander patients, Hispanic or Latino patients, and Native American patients, though not quite as bad as the odds for Black or African American patients.

Elle Crofton, a first-year rider diagnosed with a blood cancer nine years ago, works as an advocate for BTM alongside Falkenberg, and spoke to The Times about this issue of ethnic disparity in donors. Like Falkenberg, Crofton was able to find multiple full matches on the BTM registry that allowed her to get a transplant seven years ago, but said, For people who are not white, they have a lot less likelihood of finding a match. She added that the team is trying to get the word out to get more people of color on the registry, saying, We hope we can make the need for everyone to have that equal ability to find a match smaller.

Beyond volunteering and riding, Falkenberg and Crofton have begun legislative advocacy work, lobbying Congress to provide legal support to donors. The two reached out to Joe Neguse, the U.S. representative for Colorados 2nd Congressional District for support. Falkenberg and Crofton had a virtual meeting surrounding their current work on a Life Saving Leave Act, which Neguse co-sponsored the next day. The act would work to allow 40 hours of nonconsecutive time off of work, and protect workers from being fired while undergoing the donation process. This process includes a physical exam and an injection to increase stem cell production, so the travel and donation can take up to two days to complete. So while not a paid leave, the act would mitigate the fear for potential donors of losing their job.

Alongside the act, Be the Match reimburses for associated costs with the donation process. Its common-sense stuff, just not the law right now, Falkenberg said, and added, Unfortunately, the people that are more likely to say, Im worried about losing my job also line up with the groups underrepresented on the registry. So, every donor who donates matters.

To donate, become a donor and join the registry, or find out other ways to support the organization, visit bethematch.org. Eligibility to become a donor is met if you meet the health guidelines and are between 18 and 40 years old. For registration, completion of a health history form and a swab of cheek cells is needed. The swab kit is mailed to the registrants home.

Read more from the original source:
Blood, sweat, and many miles for cellular therapy - Martha's Vineyard Times

Posted in Connecticut Stem Cells | Comments Off on Blood, sweat, and many miles for cellular therapy – Martha’s Vineyard Times

How space technology like the James Webb telescope is improving healthcare on Earth – The National

Posted: July 27, 2022 at 2:36 am

From breast cancer treatments to self-driving cars and fitness trackers, space exploration is improving life on Earth for millions of people.

As the James Webb Space Telescope beams incredible images back to Nasa, scientists hailed the way the same technology has been used to improve eye surgery.

It is the latest example of how space research can be used in multiple formats of everyday life, particularly in improving healthcare.

The eyesight of millions has improved thanks to the technology used to build the Webb telescope over decades, by driving major improvements to Lasik eye surgery.

The same process for measuring the powerful mirrors used by the telescope to capture fragments of light from more than 13 billion years ago in deep space has been incorporated into a device to precisely measure the human eye.

The technology has been incorporated into Johnson & Johnson Visions iDesign Refractive Studio, a device that takes measurements to map imperfections in visual pathways and cornea curvature, similar to a unique optical fingerprint for each eye.

The mirrors were one of the really critical technologies we needed to develop to enable the observatory, said Lee Feinberg, optical telescope element manager for Webb at Nasas Goddard Space Flight Centre in Greenbelt, Maryland.

We had to polish them in such a way that, when they cool down, they become the mirror shape that we want.

We had to match the curvature of one mirror to the next, which was a very challenging problem.

Since the early 2,000s, the technology has been expanded and used elsewhere, including in treating people with degenerative eye conditions.

Johnson & Johnson Vision, which is headquartered in Santa Ana, California, acquired the technology in 2017, incorporating it into its iDesign Refractive Studio, which won approval from the US Food and Drug Administration in 2018.

It has been used in more than 18 million successful procedures worldwide by eye doctors in 47 countries.

Although Nasa didnt invent the technology used in thousands of hospitals around the world, the same digital image processing technique was used to enhance photographs of the moon.

That eventually led to the evolution of computerised tomography used daily in MRI and CT scans to provide potentially life-saving images for doctors.

Space engineers worked alongside doctors to develop an artificial heart pump in 1995 that uses similar technology intended for space shuttle fuel injectors.

The lifesaving device pumps blood from the heart to the rest of the body via a control unit and battery pack and acts as a stop-gap for patients awaiting a heart transplant.

The next-generation foam used to insulate the external tanks of the space shuttle has since been used to build moulds for amputees.

The materials used are affordable and robust, making them perfect for the development of artificial limbs.

The Nasa technology was originally developed for experiments to grow plants in space. For more than a decade it has been used to reduce the painful side effects of chemotherapy in cancer patients and those receiving a stem-cell transplant.

Trials of a High Emissivity Aluminiferous Luminescent Substrate, or Heals device, at the University of Alabama at Birmingham Hospital, found a 96 per cent improvement in pain management in those who used LEDs (a semiconductor light source that emits light when current flows through it).

The light sources release energy in the form of photons, that stimulate cells to aid the healing process.

Wearable devices to measure biometric activity are commonplace. But the EmbracePlus smartwatch designed to monitor astronauts during deep space exploration is now being used to monitor patients.

It offers doctors real-time monitoring of physiological data of patients to help collect valuable information for research studies and clinical trials. It is proving particularly effective in neurology, by advancing the research on those with Alzheimers, dementia or brain injuries when it can be difficult to get accurate patient-generated data.

Nasa has developed its Deep Space Networks a GPS navigation system for space. The technology relies on atomic clocks for the precise accuracy required during huge distances.

The refined lasers and oscillators used in the technology can help with communications on Earth and range-finders for self-driving cars.

Updated: July 23, 2022, 8:34 AM

Read more:
How space technology like the James Webb telescope is improving healthcare on Earth - The National

Posted in Alabama Stem Cells | Comments Off on How space technology like the James Webb telescope is improving healthcare on Earth – The National

How COVID-19, Long COVID, and COVID Vaccines Differ Between Males and Females – CreakyJoints

Posted: July 27, 2022 at 2:36 am

Throughout the pandemic, scientists have discovered that being biologically male or female might impact you when it comes to COVID-19 outcomes, long COVID, and vaccine responses but the reasons for these differences have yet to be fully understood.

While experts investigate this topic (many are calling for more studies that look at outcomes based on sex), its important to know how your sex may affect your risk, particularly if youre immunocompromised. This should be part of the ongoing conversation you have with your doctor to determine your risk level and your strategy for protecting yourself against COVID-19.

Heres what we know about the differences in COVID-19 between males and females so far and what it may mean for you.

While researchers agree that males die of COVID-19 at a higher rate than females, its not entirely clear why. A series of social factors may play a bigger role than biological differences, per a February 2022 Harvard GenderSci Lab study of more than 30 million confirmed coronavirus cases in the United States.

The team found that males were infected and died at higher rates than females in some states, but these rates were about even in other states. And at certain points during the pandemic, females outpaced males in cases and fatalities. Because of this, looking at the aggregate data for the nation could be misleading.

Whats more, the gap between males and females was smaller than what experts originally thought: Early on, it was reported that males were dying of COVID-19 at twice the rate of females. However, the data from the teams tracker showed that males in the United States had a mortality rate that was just 10 to 20 percent higher than that of females between April 2020 and May 2021.

After statistical modeling, the researchers found that 30 percent of this variation was due to state-level factors, such as differences in public health policies, timing and length of mask mandates, and other social factors like gendered health behaviors, occupational exposures, pre-existing health conditions, and demographics including race, age, and education.

The model also showed that 10 percent of the difference was based on when a measurement was taken during the pandemic.

The remaining 60 percent of the variation was not explained by either time or state. Still, researchers dont believe that interventions centered on sex-related biological factors like the use of testosteron blockers or estrogen would have a significant impact on outcomes.

Without considering [social and contextural] factors, youre missing part of the picture of why people might be getting exposed or getting a more severe case, Tamara Rushovich, a graduate student at the T.H. Chan School of Public Health and part of the GenderSci Lab research team, told The Harvard Gazette. For example, when you see numbers that show different rates of cases or deaths, its not just biology, but what was your exposure risk? And thats influenced by things like your occupation or your income.

Gendered behaviors can also play a role in the different outcomes between males and females.

Thereve been studies that look at things like adherence to mask policies or social-distancing guidelines, added Rushovich. They saw differences in gender adherence to those, so men being less likely to wear masks properly or to adhere to social distancing guidelines.

For instance, an October 2020 study in the Proceedings of the National Academy of Sciences of the United States of America looked at the gender differences in COVID-19 attitudes and behavior from eight countries. Researchers found that 59 percent of females considered COVID-19 to be a very serious problem during the first wave of the pandemic (March 16-30, 2020) across all eight countries studied (Australia, Austria, France, Germany, Italy, New Zealand, United Kingdom, and the United States), compared to just 48.7 percent of the males.

In both periods studied (including the second period from April 15-20, 2020), individuals were asked to evaluate how strictly they were following seven recommended rules, including keeping physical distance from others or staying at home. Compliance was markedly higher in females (by 5 to 6 percent), but smaller than the differences in beliefs about the pandemic.

And even after adjusting for sociodemographic characteristics and employment status, females were much more likely than males to believe that the health consequences of the pandemic were very serious and were also more supportive of restraining measures and more compliant with public health and social distancing measures, per the researchers.

The risk of severe COVID-19 outcomes may be further heightened in certain immunocompromised populations. In an April 2021 review in the Journal for ImmunoTherapy of Cancer, researchers found that individuals who were hematopoietic stem cell transplant (HCT) recipients had a 68 percent rate of 28-day survival after COVID-19 with risk factors for mortality including being male, being older than 50 years, and getting infected within 12 months after HCT.

Likewise, the COVID-19 Global Rheumatology Alliance (GRA) has looked at factors associated with COVID-19 mortality in 3,729 patients with rheumatic diseases. Being male, having an older age, and living with certain comorbidities (hypertension, heart disease, and chronic lung disease) were risk factors for COVID-19-related death. More rheumatic disease activity and certain medications (like rituximab) also raised risk.

On the other hand, some research shows that females might be more likely to encounter long COVID than males but additional studies are needed to confirm this.

A June 2022 review in Current Medical Research and Opinion found that the likelihood of having long-COVID syndrome was 22 percent greater among females. In particular, female patients were significantly more likely to have long-COVID symptoms in the categories of psychiatric and mood (i.e. depression); ear, nose, or throat; musculoskeletal (i.e. myalgia); and respiratory.

That said, male patients were significantly more likely to have long COVID in the category of renal disorders (i.e. acute kidney injury).

Differences in immune system function between females and males could be an important driver of sex differences in long COVID-19 syndrome, note the researchers. Females mount more rapid and robust innate and adaptive immune responses, which can protect them from initial infection and severity. However, this same difference can render females more vulnerable to prolonged autoimmune-related diseases.

As with Lyme disease, the COVID-19 pathogen might remain hidden and generate greater levels of inflammatory cytokines in females than males, per a February 2022 review in the European Respiratory Journal. Some experts believe that fragments of SARS-CoV-2 could hang around areas of the body like the kidneys or brain, sparking a chronic inflammation-associated cascade. This may result in symptoms like pain or brain fog.

In general, 80 percent of all individuals affected by autoimmune disorders are females, due to variation within the sex chromosomes and hormonal changes, per a May 2020 review in Cureus. (An increasing body of research has pointed toward the possibility that COVID-19 causes the development of autoantibodies linked to other autoimmune diseases and may be tied to long-COVID symptoms.)

All of this said, most studies on long COVID do not evaluate or report granular data by sex, so more research in this area will be key for better understanding the risk of long COVID.

The lack of studies reporting sex-disaggregated outcomes for COVID-19 speaks to the need for further, large-scale research that includes sex as an analytical variable and that reports data by sex, note the researchers of the Current Medical Research and Opinion review.

Its important to talk to your doctor about your risk of long COVID as an immunocompromised patient and how your sex might play a role in that risk.

I have not seen data to suggest confirming that immunocompromised patients are more likely to develop long COVID than patients who are not immunocompromised, Samoon Ahmad, MD, clinical professor of psychiatry at NYU Grossman School of Medicine, told us previously. That said, its clear that immunocompromised patients are more likely to develop severe COVID if they get it and research suggests that people who have severe COVID are more likely to develop long COVID.

Read more about what you should know about long COVID.

Individuals who are biologically male or female also have differences when it comes to the COVID-19 vaccine, whether its in regards to vaccine hesitancy or risk of adverse effects.

Initially, females were more hesitant than males to get the COVID-19 vaccine. In a review of 60 studies published in the Journal of Public Health, researchers found that 58 percent of papers reported males having higher intentions to get vaccinated against COVID-19. Significantly fewer females stated that they would get vaccinated than males during the time period studied (November 2020 to January 2021).

Overall, males were on average 41 percent more likely to report that they intended to receive a vaccine rather than being unwilling or undecided compared with females. The gender effects were even higher among health care workers compared with unspecified population samples. (That said, this result requires cautious interpretation, given that gender proportions in the health care worker samples were highly unbalanced and the number of studies with health care worker samples was comparatively small.)

However, many of the studies included in this review asked individuals about their intentions to get vaccinated before a vaccine was available.

By April 2021, more females than males had gotten vaccinated in many states, per the Kaiser Family Foundation. The vaccine breakdown between males and females was generally close to 60 percent and 40 percent for instance, 58 percent of those vaccinated in Alabama were females and 57 percent were females in Florida.

There may be many reasons for this difference: For instance, females make up three-quarters of the workforce in health care and education, which were sectors prioritized for initial vaccines. Females also tend to have longer life spans, so older individuals initially eligible for vaccines were more likely to be female. However, the gender gap continued even as eligibility expanded to all adults.

When it comes to rare adverse reactions to the vaccines, males and females also appear to be affected differently. In a February 2022 review in the journal Vaccines, researchers found that the risk of adverse events after the Pfizer-BioNTeach COVID-19 vaccine were consistently higher in females of all ages. This included local responses such as pain at the injection site, systemic events such as fever, and sensory events such as paresthesia (a burning, prickling sensation) in the hands and face.

Females may have increased reactogenicity of vaccines and are at higher risk of anaphylaxis, per the review.

The remarkably consistent excess in the rates of adverse events in females following immunization with the Pfizer-BioNTech COVID-19 vaccine, in all age groups, suggests that gender-specific factors influence the response to the vaccine, note the researchers. These findings indicate that different doses of the vaccine for men and women should be explored.

Females also report more vaccine side effects in general. More than 79 percent of nearly 7,000 reports processed through the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System from December 14, 2020 to January 13, 2021 came from females, per the CDCs Morbidity and Mortality Weekly Report. The most frequently reported symptoms were headache, dizziness, and fatigue.

This could be due to females greater immune response. From a biological perspective, women and girls produce sometimes twice as many infection-fighting antibodies from vaccines, said Rosemary Morgan, a research scientist at Johns Hopkins Bloomberg School of Public Health, told USA TODAY.

Whats more, male sex hormones like testosterone and dihydrotestosterone (DHT) have immunosuppressive qualities because of the way they modulate the breakdown of fat, per St. Lukes Health. Some research has shown that males have lesser antibody responses and lesser inflammatory cytokine expression when given the flu shot than females.

However, this doesnt appear to affect COVID-19 vaccine efficacy rates which were actually slightly higher for males than females in clinical trials. For instance, clinical trials showed that the Moderna vaccine was 95.4 percent effective at preventing COVID-19 in males, compared to 93.1 percent for females. For the Pfizer vaccine, efficacy was 96.4 percent in males and 93.7 percent in females.

One study in the journal Molecular Pharmacology looked at whether fat-based nanoparticles could be the cause behind the difference in vaccine efficacy. Researchers found that there were significant differences in the uptake of these nanoparticles between male and female natural killer cells (a type of immune cell that has small particles with enzymes that can kill cells infected with a virus).

The results of this proof-of-concept study show the importance of recipient sex as a critical factor which enables researchers to better consider sex in the development and administration of vaccines for safer and more-efficient sex-specific outcomes, note the researchers.

If youre immunocompromised, youre likely already mindful of mitigation efforts to protect yourself against COVID-19. While being biologically male or female isnt likely to make a major impact on your risk of severe disease (unless you partake in behavior that increases your risk), it might affect your chances of long COVID.

And while its possible you may have a slightly higher risk of an adverse reaction to the vaccine if youre female, such reactions are rare. In most cases, the benefits of the COVID-19 vaccine outweigh the risks.

Of course, as an immunocompromised patient, its important to be aware of every tool you have to protect yourself and to stay aware of your risks. For instance, you should have a conversation with your doctor about your risk level for long COVID should you get infected (and how your sex may play a role in that risk).

Although we still have much to learn about the differences between females and males when it comes to COVID-19, you can use the clues available to create the best-informed strategy to protect yourself in partnership with your doctor.

Join the Global Healthy Living Foundations free COVID-19 Support Program for chronic illness patients and their families. We will be providing updated information, community support, and other resources tailored specifically to your health and safety.Join now.

More:
How COVID-19, Long COVID, and COVID Vaccines Differ Between Males and Females - CreakyJoints

Posted in Alabama Stem Cells | Comments Off on How COVID-19, Long COVID, and COVID Vaccines Differ Between Males and Females – CreakyJoints

Self-organized anteroposterior regionalization of early midbrain and hindbrain using micropatterned human embryonic stem cells – Newswise

Posted: July 27, 2022 at 2:35 am

Abstract: To develop into the central nervous system, neuroepithelial cells must first form a neural tube consisting of a series of patterned neural progenitor cells along the anterior-posterior (AP) axis. Based on studies using model organisms, it has been revealed that AP spatial regionalization is dominated by gradients of morphogens that regulate retinoic acid (RA), sonic hedgehog (SHH), bone morphogenetic proteins (BMPs), and Wingless/int1 (WNT) signaling pathways. Recently, human pluripotent stem cells (hPSCs) were successfully induced into a patterned neural tissue with differential AP gene expression levels by a gradient of WNT activity controlled by a microfluidic device. However, the midbrain and hindbrain boundaries were not as sharp as observed in vivo, likely due to the lack of additional important morphogenic factors, such as RA and SHH. Here, we induced micropatterned hPSCs into AP patterned neural tissue by activating not only WNT but also RA and SHH signals under fully defined culture conditions. We found that hPSCs self-organized into spatially patterned midbrain (FOXG1-OTX2+) and hindbrain (HOXB4+) progenitors with a sharp boundary after 6 days of induction. Following the initial induction, the cells with midbrain identities near the pattern boundary folded inwardly to form a 3D structure, maintaining a distinct boundary between OTX2+ and HOXB4+ zones. To investigate the mechanism of cell fates patterning, we found that the reaction-diffusion of BMP/Noggin played a role in AP regionalization, while differential mechanical stress and cell sorting were unlikely to be involved. Then, we validated our model by investigating the effects of exposure to two known teratogens including valproic acid and isotretinoin. Drug treatment results successfully predicted that valproic acid inhibited the development of both midbrain and hindbrain development while isotretinoin disrupts the normal AP patterning of the midbrain and hindbrain. In conclusion, by integrating engineering approaches and chemically defined culture conditions, we have developed an in vitro AP patterned model of early human midbrain and hindbrain development, and we have revealed its potential to be employed as a high throughput drug discovery system.

Visit link:
Self-organized anteroposterior regionalization of early midbrain and hindbrain using micropatterned human embryonic stem cells - Newswise

Posted in Stem Cells | Comments Off on Self-organized anteroposterior regionalization of early midbrain and hindbrain using micropatterned human embryonic stem cells – Newswise

Synthetic Stem Cells Market 2022 Size, Share, Future Plans, Competitive Landscape and Forecast to 2030 This Is Ardee – This Is Ardee

Posted: July 27, 2022 at 2:35 am

Global Synthetic Stem Cells Market is valued at approximately USD $billion in 2021 and is anticipated to grow with a healthy growth rate of more than % over the forecast period 2022-2028.

Stem cell therapies work by promoting endogenous repair that is, they help damaged tissue in repairing itself by secreting paracrine factors, including proteins and genetic materials. While stem cell therapies can be effective, they are also associated with some risks of both tumor growth and immune rejection. The increasing incidences of various cardiovascular diseases and government investment in research & development activities have led to the adoption of Synthetic Stem Cells across the forecast period.

Download Free Sample of This Strategic Report :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5492

For Instance: as per the WHO, An estimated 17.9 million people died from CVDs in 2019, representing 32% of all global deaths. Of these deaths, 85% were due to heart attack and stroke. Also, with the development of stem cells for stem line banking, the adoption & demand for Synthetic Stem Cells is likely to increase the market growth during the forecast period. However, unclear and unstructured regulations impede the growth of the market over the forecast period of 2022-2028.

The key regions considered for the Global Synthetic Stem Cells Market study include Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world in terms of market share owing to the growing investment in research and development activities. Whereas, Asia-Pacific is also anticipated to exhibit the highest growth rate over the forecast period 2022-2028. Factors such as rising population, rising incidences of injuries and improving healthcare infrastructure would create lucrative growth prospects for the Synthetic Stem Cells Market across Asia-Pacific region.

SPECIAL OFFER (Avail an Up-to 30% discount on this report :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5492

Major market players included in this report are:

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

Access full Report Description, TOC, Table of Figure, Chart, etc :-https://reportocean.com/industry-verticals/sample-request?report_id=bw5492

By Application:

Cardiovascular Disease

Neurological Disorders

Cancer

Diabetes

Gastrointestinal

Musculoskeletal Disorder

By End Use:

Hospitals and Surgical Centers

Academic Institutes

Research Laboratories

Pharmaceutical and Biotechnology Companies

Others

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Table of Content

Access Full Report, here:-https://reportocean.com/industry-verticals/sample-request?report_id=bw5492

About Report Ocean:We are the best market research reports provider in the industry. Report Ocean believes in providing quality reports to clients to meet the top line and bottom line goals which will boost your market share in todays competitive environment. Report Ocean is a one-stop solution for individuals, organizations, and industries that are looking for innovative market research reports.

Get in Touch with Us:Report Ocean:Email:sales@reportocean.comAddress: 500 N Michigan Ave, Suite 600, Chicago, Illinois 60611 UNITED STATES Tel: +1 888 212 3539 (US TOLL FREE)Website:https://www.reportocean.com/

See the article here:
Synthetic Stem Cells Market 2022 Size, Share, Future Plans, Competitive Landscape and Forecast to 2030 This Is Ardee - This Is Ardee

Posted in Stem Cells | Comments Off on Synthetic Stem Cells Market 2022 Size, Share, Future Plans, Competitive Landscape and Forecast to 2030 This Is Ardee – This Is Ardee

Global Research Antibodies & Reagents Markets, 2022-2027 – Growth in Stem Cell and Neurobiology Research / Increasing Focus on Biomarker Discovery…

Posted: July 27, 2022 at 2:35 am

DUBLIN, July 25, 2022 /PRNewswire/ -- The 'Global Research Antibodies & Reagents Market by Product (Antibodies (Type, Form, Source, Research Area), Reagents), Technology (Western Blot, Flow Cytometry, ELISA), Application (Proteomics, Genomics), End-user (Pharma, Biotech, CROs), and Region - Forecast to 2027'report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global research antibodies and reagents market is projected to reach USD 16.1 billion by 2027 from USD 11.6 billion in 2022, at a CAGR of 6.7%

The research antibodies and reagents market evolved owing to factors such as increasing proteomics and genomics research, growing demand for antibodies for research reproducibility, and increasing R&D expenditure in the life sciences industry.

Driven by the increasing demand for personalized medicine and structure-based drug design. It is expected that the global research antibodies and reagents market will witness significant growth in the coming years.

On the basis of product, the reagents segment holds the highest market share during the forecast period

On the basis of product, the research antibodies and reagents market are segmented into reagent and antibodies. In 2021 the reagent segment accounted for the larger market share. Factors such as increasing applications of biosciences and biotechnology within the healthcare and pharmaceutical fields is driving the market.

On the basis of technology, the flow cytometry segment is expected to register the highest CAGR during the forecast period

On the basis of technology, the research antibodies and reagents market is segmented into western blotting, flow cytometry, ELISA, Immunohistochemistry, Immunofluorescence, Immunoprecipitation, and other technologies. During the forecast period the flow cytometry segment is expected to witness the highest growth.

Factors such as advantages of this technique, its ability to perform simultaneous multi-parameter analysis on single cells within a heterogeneous mixture, offering high throughput along with technological innovations in flow cytometry and increasing oncology research, are driving the growth of this segment.

On the basis of application, the proteomics segment holds the highest market share during the forecast period

On the basis of application, the research antibodies and reagents market is segmented into proteomics, drug development and Genomics. In 2021, Proteomics held the largest share of the global research antibodies and reagents market. Factors such as increasing efficiency maps drug-protein and protein-protein interactions.

Story continues

Additionally, proteomic technologies have minimized the cost, time, and resource requirements for chemical synthesis and biological testing of drugs and are highly efficient. Such factors are driving the market.

On the basis of end-user, the pharmaceutical & biotechnology segment holds the highest market share during the forecast period

The research antibodies and reagents market is divided into the pharmaceutical & biotechnology companies, academic & research institutions and Contract Research Organizations.

In 2021 the pharmaceutical & biotechnology companies held the largest share of the global research antibodies and reagents end-user market. Factors such as growing use of research antibodies in drug development for the identification and quantification of biomarkers and other techniques are driving the market.

By Region, Asia Pacific is expected to register the highest CAGR during the forecast period

During the forecast period (2022 to 2027), the Asia Pacific research antibodies and reagents market is expected to grow at the highest CAGR. Factors such as increasing research in proteomics and genomics and growing research funding, investments by pharmaceutical and biotechnology companies, and growing awareness in the region are driving the market in the region.Key Players

The key players operating in the research antibodies and reagents systems include Thermo Fisher Scientific, Inc. US), Merck KGaA (Germany), Abcam plc (UK), Becton, Dickinson and Company (US), Bio-Rad Laboratories (US), Cell Signaling Technology (US), F. Hoffmann-La Roche (Switzerland), Danaher Corporation (US), Agilent Technologies (US), PerkinElmer (US), Lonza (Switzerland), GenScript (China), and BioLegend (US).

Premium Insights

Increasing R&D Expenditure in the Life Science Industry to Drive Market Growth

Proteomics Accounted for the Largest Share of the Asia-Pacific Research Antibodies and Reagents Market in 2021

China Shows the Highest Revenue Growth Opportunities During the Forecast Period

North America Will Continue to Dominate the Research Antibodies and Reagents Market Until 2027

Developing Markets to Register a Higher Growth Rate in the Forecast Period

Market Dynamics

Drivers

Restraints

Opportunities

Emerging Markets

Personalized Medicine and Protein Therapeutics

Growth in Stem Cell and Neurobiology Research

Increasing Focus on Biomarker Discovery

Rising Interest in Outsourcing

Challenges

Industry Trends

Increasing Research on Therapeutic Antibodies

Recombinant Antibodies Supporting the Smooth Transition from in Vitro to in Vivo

Growing Consolidation of the Life Sciences Market for Antibodies and Reagents

Stakeholder Analysis

Impact of COVID-19 on the Research Antibodies and Reagents Market

Supply Chain Analysis

Technology Analysis

Regulatory Analysis

Porter's Five Forces

Companies Mentioned

Abcam plc

Agilent Technologies, Inc.

Analytik Jena AG

Atlas Antibodies

BD

Bio-Rad Laboratories, Inc.

Biolegend

Cell Signaling Technology, Inc.

Danaher Corporation

Dovetail Genomics

F. Hoffmann-La Roche

Fujirebio Diagnostics AB

Genscript

Illumina, Inc.

Immunoprecise Antibodies Ltd

Lonza

Merck KGaA

Omega Bio-Tek

Perkinelmer, Inc.

Thermo Fisher Scientific, Inc.

For more information about this report visit https://www.researchandmarkets.com/r/ocfjjw

Media Contact:

Research and MarketsLaura Wood, Senior Managerpress@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470For U.S./CAN Toll Free Call +1-800-526-8630For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

Cision

View original content:https://www.prnewswire.com/news-releases/global-research-antibodies--reagents-markets-2022-2027---growth-in-stem-cell-and-neurobiology-research--increasing-focus-on-biomarker-discovery--rising-interest-in-outsourcing-301592275.html

SOURCE Research and Markets

Go here to see the original:
Global Research Antibodies & Reagents Markets, 2022-2027 - Growth in Stem Cell and Neurobiology Research / Increasing Focus on Biomarker Discovery...

Posted in Stem Cells | Comments Off on Global Research Antibodies & Reagents Markets, 2022-2027 – Growth in Stem Cell and Neurobiology Research / Increasing Focus on Biomarker Discovery…

DNA recombinations are widespread in human genomes and are implicated in both development and disease – EurekAlert

Posted: July 27, 2022 at 2:35 am

Scientists from the RIKEN Center for Integrative Medical Sciences in Japan in collaboration with other researchers from around the world have discovered that recombinations of specific genomic sequences that are repeated millions of times in the genome of each of our cells are pervasively found in both normal and in disease states. Identifying the mechanisms that lead to this myriad of recombinations involving DNA sequences that were once considered as junk, may be crucial to understanding how our cells develop and what can make them unhealthy.

Following the discovery of DNA, it was long believed that all the cells in our body share the same genetic code, safely guarded within the nucleus. However, modern advances in DNA sequencing have challenged this view: we now know that mutations accumulate in the genome of single cells starting from the very early stages of development. However, the magnitude of this phenomenon and how it contributes to disease is not well understood.

In this work, published in Cell, the authors looked at certain repeated genomic sequences, called Alu and L1, and developed a method to study these specific sequences of DNA that are repeated millions of times in the genome of each cell. It was already known that they recombine with each other, generating mutations often found in cancer and other genetic disorders. By analyzing the DNA of donors unaffected by disease, the researchers identified millions of DNA mutations caused by the recombination of these repeated sequences, and further discovered that different tissues in the body are characterized by different recombination signatures.

The researchers also found that the differentiation of human stem cells into neuronal cells is accompanied by distinct changes of recombination of repeat sequences. This indicates that this particular type of DNA mutation may be a physiological phenomenon involved in human development.

Finally, the researchers looked at the recombination of repeated sequences in samples from people affected by Alzheimer's and Parkinson's disorders, the two most prominent neurodegenerative disorders in the developed world. They found signatures of recombination that are specific to each disease, suggesting that genomic recombinations caused by these repeated sequences are involved in brain diseases.

According to Giovanni Pascarella, first author of the study, "We have shown in this study that the recombination of repeat elements in the human genome is a widespread phenomenon that contributes to the complex constellation of genomic variants making up our genomes."

According to, Piero Carninci, Principal Investigator and co-corresponding author of the study, "We hypothesize that it might be that random recombinations of Alu and LI in somatic cells may occasionally prime the genome of individual cells at vulnerable sites and drive the transition from healthy to pathological states."

"However," he continues, "what is difficult to know at this point is to determine whether the recombinations in disease are truly causative or if they are effects of the disease state. Further studies need to be done to understand this important question."

Experimental study

Cells

Recombination of repeat elements generates somatic complexity in human genomes

25-Jul-2022

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Read more from the original source:
DNA recombinations are widespread in human genomes and are implicated in both development and disease - EurekAlert

Posted in Stem Cells | Comments Off on DNA recombinations are widespread in human genomes and are implicated in both development and disease – EurekAlert

What lab-grown cerebral organoids are revealing about the brain – New Scientist

Posted: July 27, 2022 at 2:35 am

Blobs of human brain cells cultivated in the lab, known as brain organoids or mini-brains, are transforming our understanding of neural development and disease. Now, researchers are working to make them more like the real thing

By Clare Wilson

Neil Webb

A DOZEN tiny, creamy balls are suspended in a dish of clear, pink liquid. Seen with the naked eye, they are amorphous blobs. But under a powerful microscope, and with some clever staining, their internal complexity is revealed: intricate whorls and layers of red, blue and green.

These are human brain cells, complete with branching outgrowths that have connected with one other, sparking electrical impulses. This is the stuff that thoughts are made of. And yet, these collections of cells were made in a laboratory in this case, in the lab of Madeline Lancaster at the University of Cambridge.

The structures, known as brain organoids or sometimes mini-brains, hold immense promise for helping us understand the brain. They have already produced fresh insights into how this most mysterious organ functions, how it differs in people with autism and how it goes awry in conditions such as dementia and motor neurone disease. They have even been made to grow primitive eyes.

To truly fulfill the potential of mini-brains, however, neuroscientists want to make them bigger and more complex. Some are attempting to grow them with blood vessels. Others are fusing two organoids, each mimicking a different part of the brain. Should they succeed, their lab-grown brains could model development and disease in the real thing in greater detail than ever before, paving the way to new insights and treatments.

But as researchers seek to make mini-brains genuinely worthy of the name, they move ever closer to a crucial question: at what point will their creations approach sentience?

The key to developing organoids was the discovery of stem cells,

More:
What lab-grown cerebral organoids are revealing about the brain - New Scientist

Posted in Stem Cells | Comments Off on What lab-grown cerebral organoids are revealing about the brain – New Scientist

Page 329«..1020..328329330331..340350..»